Sustained-release dexamethasone intravitreal implant for treatment of diabetic macular edema

References

• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care26(9), 2653–2664 (2003).
   PubMed Web of Science ®Google Scholar
• Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv. Ophthalmol.28(Suppl.), 452–461 (1984).
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. US Department of Health and Human Services, National Institute of Health, Bethesda, MD, USA (2005).
   Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology102(1), 7–16 (1995).
   PubMed Web of Science ®Google Scholar
• Ferris FL 3rd. Diabetic macular edema. In: Diabetic Retinal Renal-Syndrome. Pathogenesis and Management Update 2002. Friedman EA, L’Esperance FA Jr (Eds). Kluwer Academic Publishers, Dordrecht/Boston/London, 47–58 (2002).
   Google Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch. Ophthalmol.103(12), 1796–1806 (1985).
   PubMed Web of Science ®Google Scholar
• Tranos PG, Topouzis F, Stangos NT et al. Effect of laser photocoagulation treatment for diabetic macular oedema on patient’s vision-related quality of life. Curr. Eye Res.29(1), 41–49 (2004).
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology115(9), 1447–1459 (2008).
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology117(6), 1064–1077 (2010).
   PubMed Web of Science ®Google Scholar
• Jahn CE, Topfner von Schutz K, Richter J, Boller J, Kron M. Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy. Ophthalmologica218(6), 378–384 (2004).
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin. Ophthalmol.14(4), 223–232 (1999).
   PubMedGoogle Scholar
• Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology110(9), 1690–1696 (2003).
   PubMed Web of Science ®Google Scholar
• Hasan Q, Dafydd H, Tan ST, Xu B, Davis PF. The optimal type, dosage and timing of glucocorticoid administration for the treatment of hemangioma in vitro. J. Appl. Res.5(2), 360–370 (2005).
   Google Scholar
• Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol.341(2–3), 309–315 (1998).
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem.80(4), 667–677 (2002).
   PubMed Web of Science ®Google Scholar
• Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr. Eye Res.30(11), 949–957 (2005).
   PubMed Web of Science ®Google Scholar
• Forster C, Waschke J, Burek M, Leers J, Drenckhahn D. Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific. J. Physiol.573(Pt 2), 413–425 (2006).
   PubMed Web of Science ®Google Scholar
• Hsu J. Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol.18(3), 235–239 (2007).
   PubMed Web of Science ®Google Scholar
• Lightman S. New therapeutic options in uveitis. Eye11(Pt 2), 222–226 (1997).
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology109(5), 920–927 (2002).
   PubMed Web of Science ®Google Scholar
• Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology111(11), 2044–2049 (2004).
   PubMed Web of Science ®Google Scholar
• Lam DS, Chan CK, Mohamed S et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema six-month outcomes. Ophthalmology114(12), 2162–2167 (2007).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology113(9), 1533–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Batioglu F, Ozmert E, Parmak N, Celik S. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int. Ophthalmol.27(5), 299–306 (2007).
   PubMedGoogle Scholar
• Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J. Ophthalmol.19(2), 122–127 (2005).
   PubMedGoogle Scholar
• Jonas JB, Spandau UH, Kamppeter BA, Vossmerbauemer U, Harder B. Follow-up after intravitreal triamcinolone acetonide for diabetic macular edema. Eur. J. Ophthalmol.16(4), 566–572 (2006).
   PubMedGoogle Scholar
• Lam DS, Chan CK, Mohamed S et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br. J. Ophthalmol.91(2), 199–203 (2007).
   PubMed Web of Science ®Google Scholar
• Taban M, Singh RP, Chung JY, Lowder CY, Perez VL, Kaiser PK. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am. J. Ophthalmol.144(1), 50–54 (2007).
   PubMed Web of Science ®Google Scholar
• Maia M, Farah ME, Belfort RN et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br. J. Ophthalmol.91(9), 1122–1124 (2007).
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol.127(3), 245–251 (2009).
   PubMed Web of Science ®Google Scholar
• Pearson P, Levy B, Comstock T; Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial. Invest. Ophthalmol. Vis. Sci.47 (2006) (E-Abstract 5442).
   Google Scholar
• Campochiaro PA. Sustained release intravitreal implant II. Presented at: Angiogenesis 2010: Clinical Trials. Miami, FL, USA, 20 February 2010.
   Google Scholar
• Cunningham ET Jr, Adamis AP, Altaweel M et al. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology112(10), 1747–1757 (2005).
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol.142(6), 961–969 (2006).
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology117(6), 1078–1086 (2010).
   PubMed Web of Science ®Google Scholar
• Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M. Effect of ruboxistaurin on blood–retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest. Ophthalmol. Vis. Sci.46(10), 3855–3858 (2005).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Davis MD, Girach A et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
   PubMed Web of Science ®Google Scholar
• PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol.125(3), 318–324 (2007).
   PubMed Web of Science ®Google Scholar
• Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol. Cell. Endocrinol.246(1–2), 142–146 (2006).
   PubMed Web of Science ®Google Scholar
• Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br. J. Pharmacol.135(2), 511–519 (2002).
   PubMed Web of Science ®Google Scholar
• Yeung CK, Chan KP, Chan CK, Pang CP, Lam DS. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn. J. Ophthalmol.48(3), 236–242 (2004).
   PubMed Web of Science ®Google Scholar
• Chung H, Hwang JJ, Koh JY, Kim JG, Yoon YH. Triamcinolone acetonide-mediated oxidative injury in retinal cell culture: comparison with dexamethasone. Invest. Ophthalmol. Vis. Sci.48(12), 5742–5749 (2007).
   PubMed Web of Science ®Google Scholar
• Harrison KM, Edelman JL. Complete suppression of VEGF121 or VEGF165-mediated retinal inflammation, increases in retinal vessel caliber/tortuosity, and BRB breakdown by an intravitreal dexamethasone drug delivery system. Invest. Ophthalmol. Vis. Sci.47 (2006) (E-Abstract 504).
   Google Scholar
• Burke JA, Lin T, Zhang K-M et al. Extended effect of a dexamethasone posterior segment drug delivery system (dexDDS) on VEGF-induced retinopathy. Invest. Ophthalmol. Vis. Sci.47 (2006) (E-Abstract 4491).
   Google Scholar
• Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol.110(2), 259–266 (1992).
   PubMed Web of Science ®Google Scholar
• Lin J-EC, Attar M, Acheampong AA et al. Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci.52(1), 80–86 (2010).
   Google Scholar
• Lin J-EC, Burke JA, Peng Q et al. Pharmacokinetics of a sustained release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest. Ophthalmol. Vis. Sci. (2010) (In press).
   Google Scholar
• Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina25(5), 556–560 (2005).
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol.125(3), 309–317 (2007).
   PubMed Web of Science ®Google Scholar
• Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina29(1), 46–51 (2009).
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S et al.; for the Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (2010) (In press).
   Google Scholar
• Blumenkranz MS, Haller JA, Kuppermann BD et al. Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina30(7), 1090–1094 (2010).
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS et al.; Dexamethasone DDS Phase II study group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol.128(3), 289–296 (2010).
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology110(4), 681–686 (2003).
   PubMed Web of Science ®Google Scholar
• Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am. J. Ophthalmol.144(1), 124–126 (2007).
   PubMed Web of Science ®Google Scholar
• Callanan DG, Gupta S, Ciulla TA et al. Safety and efficacy of dexamethasone intravitreal implant plus laser photocoagulation versus laser alone for treatment of diabetic macular edema. Presented at: American Academy of Ophthalmology Annual Meeting. Chicago, IL, USA, 16–19 October 2010 (Poster P0525).
   Google Scholar